Biovian Invests €50 Million in Manufacturing Facility in Finland
The expansion project is aimed to be completed in December 2024 and the new facility will be fully operational by 2025.
Biovian Oy announced a major investment of over €50 million to expand its manufacturing facility in Turku, Finland on July 26, 2023. The new facility plans to include house cutting-edge equipment and advanced technologies to support Advanced Therapy Medicinal Products (ATMP), such as adenoviral and adeno-associated viral (AAV) therapies.
According to the press release, it will feature dedicated Class A to D cleanroom areas for bulk drug substances and final drug product manufacture. Additionally, the expanded facility will follow current good manufacturing practices (cGMP) and fulfill both EU and US GMP requirements.
The expansion project is aimed to be completed in December 2024 and the new facility will be fully operational by 2025. Further, the investment hopes to create 100 job opportunities in the region.
Source: Biovian
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
